Transmedics Group Inc (TMDX) Stock Price, Quote & News

Company Profile

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of...

Industry: Medical Devices

Sector: Healthcare

Phone: 978 552 0900

Website: www.transmedics.com

Address:

200 Minuteman Road, Suite 302, Andover, United States

SternInvesting10 Aug. 18 at 7:15 PM

$TMDX $KVYO Just fucking pathetic

1 · Reply

ripster47 Aug. 18 at 4:57 PM

$TMDX $IBM keeping portfolio stable Most other names are down on longterm had to cut losers on AVGO QCOM check our portfolio tenetresearch.ai

0 · Reply

Guchelo Aug. 18 at 4:36 PM

$TMDX trend is your friend 😉

0 · Reply

chrsc Aug. 18 at 4:23 PM

$TMDX bright spot on a tough day!

0 · Reply

SternInvesting10 Aug. 18 at 4:01 PM

$TMDX time to sell off this weak pathetic “pump” on low volume

0 · Reply

Valueforall Aug. 18 at 2:40 PM

$TMDX Btw I am in the base to Bull case on this one $TMDX Valuation Case: Bear Case ($55–$65): Aviation fleet capex and logistics scaling permanently compress EBIT margins below 10%, while regulatory audit frictions/NORS competition cap organ volume market share, compressing the EV/S multiple down to ~3.5x. Base Case ($110–$125): Core OCS perfusion adoption drives 20%+ top-line CAGR ($750M+ FY26 guidance) with logistics network optimization stabilizing gross margins near 60%, maintaining a dominant category monopoly and supporting a ~6x EV/S re-rating. Bull Case ($160–$180+): Full operational leverage takes hold as international expansion, next-gen kidney perfusion platforms, and warm-ischemia market expansion push gross margins toward 65%+ and net margins to 20%, unlocking $1.2B+ revenue run-rate and $150M+ FCF by 2028. Asymmetric risk profile heavily skewed to the upside

0 · Reply

Valueforall Aug. 18 at 2:34 PM

$TMDX I have been invested in tmdx since it got caught in the $60’s but we were new to the position and wrote $85 / $90 calls as buffer. With this latest move it’s gonna require a new position with no strings attached so we can let this run! It feels really good investing in a company like this. The lives affected and videos I have seen of unused organs that just didn’t make it is heartbreaking. You are invested in a team that is working to not only make lives better but just make lives.

0 · Reply

Twister8 Aug. 18 at 2:11 PM

$TMDX 94.61 gap fill, expect resistance.

0 · Reply

Ducmanallja Aug. 18 at 1:56 PM

$TMDX is it $94 the gap fill?

0 · Reply

TriGuy8542 Aug. 17 at 5:38 PM

$TMDX sell puts, the worst is behind us

1 · Reply

Market Cap	3.05B
Revenue (ttm)	605.49M
Net Income (ttm)	190.29M
EPS (ttm)	N/A
PE Ratio	44.96
Forward PE	60.26
Profit Margin	31.43%
Debt to Equity Ratio	0.12

Volume	778,000
Avg Vol	1,012,476
Day's Range	N/A - N/A
Shares Out	34.56M
Stochastic %K	90%
Beta	1.90
Analysts	Sell
Price Target	$94.18